Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...

When Page Campbell's doctor recommended she try an injectable prescription drug called Wegovy to lose weight before ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Analysts forecast explosive growth ahead for AI in healthcare, with MarketsandMarkets projecting the market to surge past $110 billion by 2030 on a 38.6% compound annual growth rate. Accenture goes ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

A new frontier into advancing treatments for children and adults with bone marrow failure, leukaemia and other blood disorders will be achieved under a new partnership between Murdoch Children's ...

Wall Street extends its winning streak as markets rally on hopes that Trump will ease tariffs following recent trade ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the ...